- cafead Jun 03, 2021 at 11:22: PM
via Sanofi’s experimental breast cancer treatment amcenestrant in combination with Pfizer’s Ibrance is showing promising anti-tumor activity in postmenopausal women with metastatic breast cancer. Data from an early analysis of a Phase I/II study will be one of the highlights the French pharma giant showcases at the American Society of Clinical Oncology meeting.
article source
article source